Walgreens Boots Alliance
Q1 2023 Earnings Call
Jan 05, 2023, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Walgreens Boots Alliance first-quarter 2023 earnings conference call. [Operator instructions] Thank you.
Tiffany Kanaga, vice president of global investor relations, you may begin your conference.
Tiffany Kanaga -- Vice President, Global Investor Relations
Good morning. Thank you for joining us for the Walgreens Boots Alliance earnings call for the first quarter of fiscal year 2023. I'm Tiffany Kanaga, vice president of global investor relations. Joining me on today's call are Roz Brewer, our chief executive officer, and James Kehoe, our chief financial officer.
Rick Gates, senior vice president of pharmacy and healthcare at Walgreens, will participate in Q&A. Today's call will be approximately one hour in length, including Q&A. Let me note that all references to the COVID-19 headwind include U.S. vaccines, drive-through tests and OTC tests.
As always, during the conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 2 and those outlined in our latest forms, 10-K and 10-Q, filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement after this presentation whether as a result of new information, future events, changes in assumptions, or otherwise. You can find our press release and the slides referenced on this call in the Investors section of the Walgreens Boots Alliance website.
The slides in the press release also contain further information about non-GAAP financial measures that we will discuss today during this call. I will now turn the call over to Roz.
Roz Brewer -- Chief Executive Officer
Thanks, Tiffany. And good morning, everyone. WBA entered fiscal 2023 with good momentum, and we delivered a solid start to the year. Sales grew 1% in constant currency or over 3%, excluding the headwind from AllianceRx Walgreens and tailwinds from our new healthcare assets.
The decline in adjusted EPS comes against very strong growth of 53% last year and reflects the anticipated headwinds from lapping COVID execution and our investments in the U.S. healthcare segment and labor. Our core business remains resilient despite historic macro challenges. We are driving healthy retail comp growth on top of record prior-year performances.